5:08 PM
 | 
Jun 22, 2007
 |  BC Extra  |  Top Story

CHMP backs biosimilar EPO

The EMEA's CHMP on Friday recommended that the European Commission approve three applications for a biosimilar version of epoetin alfa manufactured by Sandoz. The EC is expected to act on the recommendation within 67 days. Concurrence with the recommendation would mark the first EU approval of a biosimilar epoetin. Sandoz plans to launch the product...

Read the full 262 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >